Abstract:Individuals with steatotic liver disease experience accelerated loss of skeletal muscle mass. Loss of skeletal muscle mass in steatotic liver disease patients is more pronounced when combined with metabolic dysfunction or increased alcohol intake. Aims Identifying risk factors for sarcopenia is important due to its significant effect on health. The association between sarcopenia and the newly proposed steatotic liver disease (SLD) and its subclassification has largely been unexplored. Methods This longitudinal cohort study included 67 905 adults who underwent at least two health checkup examinations. SLD participants were categorized as cryptogenic SLD, metabolic dysfunction‐associated SLD, metabolic dysfunction‐associated alcoholic liver disease, or alcoholic liver disease. Appendicular skeletal muscle mass (ASM) was evaluated by bioelectrical impedance analysis. Results The average duration of follow‐up was 5.9 years. The annual ASM change was −31.0 g (95% CI −32.3, −29.6) and −38.3 g (−40.3, −36.3) in participants without and with SLD, respectively. When assessed based on SLD severity, annual ASM loss was fastest in SLD participants with Fibrosis‐4 score ≥1.3, followed by those with Fibrosis‐4 score <1.3 and those without SLD. In multivariable adjusted analysis, annual ASM loss was fastest in participants with metabolic dysfunction‐associated alcoholic liver disease (−49.8 g; −93.1, −6.5), followed by those with metabolic dysfunction‐associated SLD (−24.7 g; −60.4, 11.1), and alcoholic liver disease (−24.4 g; −91.1, 42.3), and slowest in those with cryptogenic SLD (reference). This pattern was more pronounced in participants with Fibrosis‐4 score ≥1.3. Conclusion The loss of skeletal muscle mass was fastest in the participants with metabolic dysfunction‐associated alcoholic liver disease, followed by participants with metabolic dysfunction‐associated SLD, alcoholic liver disease, and cryptogenic SLD. Particular attention to prevent sarcopenia should be given to SLD patients with cardiometabolic risk factors or alcohol consumption, especially in patients with advanced fibrosis.

Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Sarcopenia is Associated with the Presence of Nonalcoholic Fatty Liver Disease in Zhejiang Province, China: a Cross-Sectional Observational Study

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis

Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction‐associated fatty liver disease: A cross‐sectional study of NHANES 2017–2018

Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study

The presence of sarcopenia at baseline seems to affect the fibrosis amelioration in patients with metabolic dysfunction associated steatotic liver disease

Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice

Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis

New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study

Prevalence of Sarcopenia and Its Defining Components in Non-alcoholic Fatty Liver Disease Varies According to the Method of Assessment and Adjustment: Findings from the UK Biobank

Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis

The Prevalence of Sarcopenia and Its Impact on Clinical Outcomes in Lumbar Degenerative Spine Disease—A Systematic Review and Meta-Analysis

Sarcopenia modifies the associations of nonalcoholic fatty liver disease with all-cause and cardiovascular mortality among older adults

Sarcopenia in cirrhosis: Unraveling the prevalence and relationships with liver disease severity and complications

Association of muscle mass, grip strength and fat-to-muscle ratio and metabolic dysfunction-associated steatotic liver disease in a middle-to-elderly aged population

Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III